Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, parallel-control study conducted in schizophrenic
inpatients with metabolic syndrome who have been conducted with olanzapine. The purpose of
this study is to evaluate the efficacy and safety of omega-3 polyunsaturated fatty acids,
Xbox aerobic exercise and transcranial direct current stimulation( tDCS). Following a
screening period, subjects who meet the entry criteria will be randomized to treated with
omega-3 polyunsaturated fatty acids1.2mg per day, Xbox aerobic exercise 30min per day and
tDCS at 2mA, 20 min(5 session/week) for 12 weeks.